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Objectives: To determine whether there is a difference in outcome between different ovulation-
induced cycles after frozen-thawed embryo transfer (FET).
Methods: We searched the Cochrane Menstrual Disorders and Subfertility Group’s 
  trials register in May 2009, the Cochrane Central Register of Controlled Trials (Cochrane 
Library, Issue 1, 2008), ISI Web of Knowledge (1985 to August 2009), and reference lists of 
articles. Relevant conference proceedings were hand-searched and researchers in the field were 
contacted. Randomized controlled trials and retrospective studies were included, comparing the 
various cycle regimens and different methods during FET in assisted reproductive technology, 
ie, in vitro fertilization and intracytoplasmic sperm injection.
Results: Using the agonist long protocol for downregulation, five trials provided extractable 
data for live-birth rates, ongoing pregnancy, and clinical pregnancy rates following FET. One 
trial provided extractable data for clinical pregnancy rate. There was no evidence of a signifi-
cant difference in any outcome between the users of urinary gonadotropins versus recombinant 
follicle-stimulating hormone. Data on implantation and miscarriage rates following FET were 
not available for analysis.
Conclusions: It seems that clinical pregnancy rate after FET is not influenced by the type 
of gonadotropins used. Research should be directed towards improving freezing and thawing 
techniques.
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Introduction
Frozen-thawed embryo transfer (FET) has become a vital aspect of assisted 
  reproduction.1 Pregnancy rates following FET treatment have always been lower than 
following fresh embryo transfer. Nevertheless, FET increases the cumulative pregnancy 
rate, reduces cost, is relatively simple to undertake, and can be accomplished in a 
shorter time period compared with repeated “fresh” cycles. FET is performed using 
different cycle regimens,2 ie, spontaneous ovulatory cycles, cycles in which ovula-
tion is induced by drugs, and cycles in which the endometrium is artificially prepared 
using oestrogen and progesterone hormones, with or without a gonadotropin-releasing 
hormone (GnRH) agonist. Results of fresh and FET in women undergoing in vitro 
fertilization (IVF) with GnRH agonists and GnRH antagonists showed no significant 
difference between methods.3
Little is known about the impact of type of gonadotropins on FET. In the medical 
literature, recent meta-analyses have shown a significant advantage of using urinary 
gonadotropins over recombinant follicle-stimulating hormone (rec-FSH) during ovarian International Journal of Women’s Health 2010:2 90
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stimulation, with higher clinical pregnancy and live-birth 
rates in the former group.4,5 However, these reviews did not 
directly assess the results of using different FSH preparations 
in FET cycles, nor cumulative pregnancy and live-birth rates 
per stimulated cycle.
The beneficial effect of urinary gonadotropins has 
been investigated in the Menotropin versus Recombinant 
FSH in vitro Fertilisation Trial (MERiT), which showed 
differences in embryo quality and endometrial receptivity 
between rec-FSH and highly purified human chorionic 
gonadotropin (HP-hMG).6 Balasch et al7 compared follicular 
development and estradiol levels after ovarian stimulation in 
pituitary-suppressed, normally ovulating women undergo-
ing IVF, using highly purified urinary FSH (u-FSH-HP) and 
rec-FSH. A secondary variable in their study was embryo 
implantation potential, which is closely related to appropriate 
follicular development and oocyte competence. They found 
that rec-FSH is more effective than u-FSH-HP when used in 
the same patient for inducing multiple follicular development 
in downregulated cycles, as indicated by ovarian performance 
and oocyte maturity. In addition, they concluded that rec-FSH 
yields significantly higher implantation rates than u-FSH-HP 
when used in patients undergoing their second IVF attempt.
Clinical efficiency in IVF procedures have been debated 
for years. Definition of a goal, or endpoint, for IVF treatments 
has varied between clinicians, regulatory bodies, and 
  organizations, with some regarding a clinical pregnancy, an 
ongoing pregnancy, a live birth, or even a “take-home” baby as 
the primary outcome of IVF treatments.8–21 This controversy 
has recently been complicated by the use of single embryo 
transfer to reduce the incidence of multiple births. This has 
added another variable to the equation, ie, whether a multiple 
gestation pregnancy should be considered a success or a 
failure. Regardless of the exact definition of success, the 
use of FET has undoubtedly led to more success in assisted 
reproduction. The objective of this systematic review and 
meta-analysis was to determine the effectiveness of the use 
of urinary gonadotropins versus rec-FSH in FET.
Materials and methods
In order to determine the effectiveness of cryo-embryo trans-
fers following ovarian stimulation with urinary gonadotropins 
compared with rec-FSH, we included comparative trials (ie, 
randomized controlled trials, nonrandomized controlled tri-
als, cohort studies [ﾭprospective or retrospective], and case-
control studies). Study designs were classified according to 
their methodological rigor, with lower levels of evidence 
included only if there was a lack of adequate higher quality 
evidence. Adequacy of evidence was determined after tak-
ing into consideration the number and sample sizes of the 
included studies at each level of evidence.
Participants
Participants in the included studies were women who were 
part of a couple, underwent assisted reproduction, ie, IVF 
or intracytoplasmic sperm injection (ICSI) for any cause 
of infertility, and underwent cryo-embryo transfer. Women 
undergoing transfer from donor oocytes and/or embryos were 
excluded. Duration, type (ie, primary or secondary), and cause 
of infertility were not considered as separate confounders, 
although they are presented descriptively in the overview of 
studies, along with all other possible confounding factors.
Interventions
Trials comparing women undergoing cryo-embryo transfer 
following ovarian stimulation with urinary gonadotropins 
versus rec-FSH were included. All dosages and durations 
of stimulation were included, as were different freezing and 
thawing techniques. Details of ovarian stimulation protocols, 
and freezing/thawing cycles are presented in the overview 
of studies.
Outcome measures
The primary outcome measures for this review were 
clinical pregnancy and miscarriage rates following 
cryo-embryonic transfer per woman. Secondary outcomes 
were implantation, ongoing pregnancy, and live-birth 
rates following cryo-embryonic transfer. Additionally, 
the cumulative clinical pregnancy and live-birth rates 
per woman were evaluated. The cumulative rates were 
  calculated by combining the pregnancy rates from the fresh 
and frozen-thawed cycles, when separately presented. In a 
subgroup analysis, the results for each group (eg, women 
with fresh cycles and women with frozen-thawed cycles) 
were also analysed separately from each other.
Search methods for identification  
of studies
We electronically searched the Medline, Embase, and Central 
ISI Web of Knowledge databases from 1985 to August 2009, 
as well as the Cochrane Library, Issue 3, 2009, with no 
  language barriers. We further performed hand searches of 
conference abstracts of major proceedings (eg, European 
Society of Human Reproduction and Embryology and 
  American Society of Reproductive Medicine) for the past 
five years, and the reference lists of expert-identified major International Journal of Women’s Health 2010:2 91
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review articles relevant to the present review and, in turn, 
the reference lists of included trials. We also searched 
  prospective trial registers of, eg, the World Health Orga-
nization (WHO), the ClinicalTrials.gov website, and the 
International Standard Randomized Controlled Trial Number 
(ISRCT) Registry, for citations of ongoing and unpublished 
trials.
Individual search strategies were developed for each 
database using the following MeSH terms, keywords, and a 
modified version of the Cochrane Highly Sensitive Search 
Strategy (HSSS): urinary, recombinant, follicle stimulating 
hormone, FSH, gonadotropin, gonadotropin, human meno-
pausal gonadotropin, human menopausal gonadotropin, 
urinary FSH, u-FSH, hMG, recombinant FSH, rec-FSH, 
frozen embryo transfer, frozen embryo replacement, frozen 
embryo cycle, FET, clinical pregnancy rate, and brand names 
of drugs used in treatment.
Data collection and analysis
In this meta-analysis, live birth rate after FET was the primary 
parameter. Several studies only present cumulative pregnancy 
rates (ie, their results also included pregnancy rates for fresh 
embryo transfers). For sound statistical comparison, fresh and 
FETs should be analysed separately. The effects of urinary 
gonadotropins and rec-FSH on the fresh embryo transfers 
have already been demonstrated in many studies, ie, that there 
is no significant difference in pregnancy rates. To isolate the 
pregnancy rate for FET from the cumulative pregnancy rate, 
the flow diagram shown in Figure 1 can be followed.
Of all the n patients (n1 in u-FSH and n2 in rec-FSH) who 
underwent controlled ovarian hyperstimulation in the study, 
m patients (m1 in u-FSH and m2 in rec-FSH) underwent 
oocyte retrieval, of whom p patients had oocytes retrieved 
(p1 in u-FSH and p2 in rec-FSH). From these patients, 
a total of q oocytes were obtained and inseminated via 
regular assisted reproductive technology (ART) procedures: 
(q1 in u-FSH and q2 in rec-FSH). The flow of oocyte/embryo 
assessments is illustrated in Figure 1. A total number of r 
embryos are transferred in the fresh cycles (r1 in u-FSH and 
r2 in rec-FSH), and s embryos are cryopreserved (s1 in u-FSH 
and s2 in rec-FSH). During a certain period, t embryos are 
thawed (t1 in u-FSH and t2 in rec-FSH), of which u thawed 
embryos are transferred (u1 in u-FSH and u2 in rec-FSH) in 
v patients (v1 in u-FSH and v2 in rec-FSH) and w cryocycles 
(w1 in u-FSH and w2 in rec-FSH). Finally, the clinical 
  pregnancy rate per frozen-thawed embryo cycle can be 
derived. In several studies, other units were used for the 
pregnancy rate, or even omitted. Some authors present only 
the live birth (or baby take-home) rates. Other authors present 
the data over a one-year period, instead of a cycle.
Data collection and analysis was conducted in accordance 
with guidelines presented in the Cochrane Handbook for 
Systematic Reviews of Interventions.22 A data set (N1, N2, 
M1, M2) was extracted from each study, in which N1 and N2 
subjects in the rec-FSH and urinary gonadotropins groups, 
respectively, underwent a cycle during which frozen-thawed 
embryos were replaced, resulting in M1 pregnancies in 
the rec-FSH group and M2 in the urinary gonadotropins 
group.
Dichotomous outcomes (eg, clinical pregnancy rates) 
were expressed as an odds ratio (OR) with 95% confidence 
intervals (CI) for each study. Results from each study were 
meta-analysed with the Comprehensive Meta-Analysis 
software, version 2.2046 (Biostat, Englewood, NJ) using the 
Mantel-Haenszel method with a fixed-effect model.
A standardized data extraction form was developed and 
piloted for consistency and completeness. Trials were considered 
for inclusion and trial data were extracted by one review author 
(PVG), and checked for accuracy and completeness by a sec-
ond reviewer (HAI) according to the inclusion criteria, with 
conflicts being resolved by consensus. In the event of missing 
data, corresponding authors of included studies were contacted 
for additional information.
The analysis of dichotomous data and continuous data 
was performed using a random-effects model, and the OR 
and weighted mean difference, respectively, evaluated with 
their 95% CI. P values are presented for further confirmation 
of the results. A P value of 0.05 was considered to be 
statistically significant.
In the graphical display of the analyses, an increased 
probability of a favorable outcome (ie, clinical pregnancy) 
for u-FSH would be displayed graphically to the right 
of the center line and vice versa. On the contrary, an 
increased probability of not having a detrimental outcome 
(eg, miscarriage) from u-FSH would be displayed graphically 
to the left of the center line.
Unit-of-analysis issues
Given that clinical infertility trials should ideally deal with 
women and not cycles, a woman should only be included 
once (ie, one cycle per woman) in the trial, otherwise there 
would be a unit-of-analysis error. Common statistical errors 
in the design and analysis of subfertility trials have already 
been reported,23 and the typical unit-of-analysis errors in 
fertility trials are well described. The authors found that 82% 
of the 39 trials which they investigated contained at least International Journal of Women’s Health 2010:2 92
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one unit-of-analysis error, but still passed review. Other 
unit-of-analysis issues have also been addressed by Van 
Gelder.24 Each study in the underlying meta-analysis was 
critically reviewed, and errors and omissions identified by 
Vail and Gardener23 were checked.
Assessment of heterogeneity
The classical measure of heterogeneity is Cochran’s Q 
which is the weighted sum of squared differences between 
individual study effects and the pooled effect across studies. 
Also, the H and I2 statistics have been calculated and included 
in the assessment. A large value of Q indicates that there is 
significant heterogeneity between studies. The significance 
level for this statistic was set to 0.10 rather than the usual 
0.05. The I2 test describes the percentage of the variability 
in effect estimates attributable to heterogeneity rather than 
sampling error (chance), with an I2 value 50% considered 
to represent substantial heterogeneity.25
Assessment of publication bias
Publication bias was assessed by visually noting the scatter 
of the point estimates and CIs for each study and by the Trim 
and Fill method when there were at least 10 studies in an 
analysis. Since the number of included studies in all of the 
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Figure 1 Flow diagram for data extraction from trials with frozen-thawed embryo transfers.International Journal of Women’s Health 2010:2 93
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analyses was below 10, the assessment was cancelled. No 
subgroup analysis was carried out in this meta-analysis.
A priori sample size calculation
A conventional approach was used to calculate the minimum 
required sample size with four parameters: Type I error, 
power, assumptions in the first group, and expected treatment 
effect. Type I error and power were fixed at the conventional 
levels (5% for Type I error, 80% for power). Assumptions 
related to the first group were prespecified on the basis of 
previously observed data (a clinical pregnancy rate of FET 
per randomized woman of 25%), and an expected treatment 
effect of 5% was expected to be clinically meaningful. With 
these assumptions, the sample size required was 1290 for 
group 1 and 1290 for group 2. None of the analyses reached 
this level of confidence because of the lack of available data 
in the literature.
Results
Search results
Electronic and hand searches identified 265 potentially 
  relevant citations based on title/abstract screening. Of 
these, five Cochrane reviews were identified,2,26–29 two 
descriptive studies of FET,30,31 and one meta-analysis.5 
In total, 247 citations were excluded, and 18 citations to 
  comparative studies were further evaluated using the full-text 
  manuscripts.32–49 Finally, only five studies met the inclusion 
criterion.37,38,42,46,48
Before the five trials are discussed, a brief summary 
is presented of a number of papers which did not fulfill 
the inclusion criteria, but which provide interesting data 
on FET.
Oehninger et al41 presented a retrospective study with 
more than 9000 embryos which had been cryopreserved 
in gonadotropin-stimulated in vitro IVF cycles. Over 
1500 thaw and transfer cycles yielded a pregnancy rate of 
  approximately 25%. Different ovarian stimulation regimens 
(various preparations of FSH, alone or in combination with 
hMG, with or without concomitant use of a GnRH agonist) 
did not influence embryo survival or pregnancy rate. Likewise, 
the application of oocyte/embryo micromanipulation 
  techniques for assisted fertilization (ICSI for male infertility) 
or assisted hatching (performed selectively) did not have an 
impact on pregnancy results. Pregnancy outcome following 
embryo cryopreservation/thawing in IVF cycles stimulated 
with a combination of a GnRH agonist (long protocol) and 
FSH (urinary, urinary highly purified, or recombinant) were 
reported.41
In a paper by Francsovits et al,34 a total of 389 oocytes 
were collected in a human follicle stimulating hormone group 
and 415 oocytes in an rec-FSH group. Part of the embryos 
were cryopreserved and clinical pregnancy rates were similar 
in both groups (13/35 versus 11/34, respectively).
Gerli et al,36 studied 60 IVF patients undergoing embryo 
transfer for the first time and randomly allocated them into two 
groups. Group A (n = 30) had subcutaneous administration 
of u-FSH (Fostimon 75, AMSA, Italy). Group B (n = 30) 
had subcutaneous administration of u-FSH (Metrodin 75 
HP, Serono, Italy). This prospective randomized clinical 
study in an IVF embryo transfer program showed that both 
drugs were equally safe and effective. The two groups did not 
  differ in clinical pregnancy rates per attempt and per transfer. 
When frozen embryo cycles were included, the difference in 
pregnancy rate became significant.
In a study by Salumets et al,45 FET was characterized 
by impaired pregnancy outcome and increased incidence 
of pregnancy loss compared with fresh IVF/ICSI embryo 
  transfers. This study reviewed the outcome of 1242 FETs 
with respect to the age of the woman, the method of 
  fertilization, embryo quality before and after freezing, and 
the number of embryos transferred. These data revealed that 
the delivery rate after FET depended on both the woman’s 
age and the quality of embryos transferred, at the same time 
being unaffected by IVF/ICSI treatment. Ovarian stimulation 
was performed using either human menopausal or rec-FSH 
after suppression was achieved.
Lieberman et al40 reported that live birth rates were similar 
for urinary and recombinant gonadotropin preparations. They 
also reported that the implantation rates for frozen embryos 
were not significantly lower than for fresh embryos. How-
ever, no details were given about whether ovarian stimulation 
was performed using human menopausal or rec-FSH.
Wang et al47 presented a retrospective study analysing 
3570 FET cycles (involving 1438 couples) with a view to 
increasing our understanding of the clinical circumstances 
that influence the potential for embryo implantation. The 
overall implantation rate was 9.1%. The characteristics 
associated with a more favorable implantation rate were 
the success of the previous fresh embryo transfer cycle, 
age 40 years, and nontubal factor aetiology of infertility. 
However, no details were given about whether the ovarian 
stimulation was performed using human menopausal or 
rec-FSH.
Oktay et al50 carried out a meta-analysis of ICSI 
cycles with frozen-thawed oocytes in comparison with a 
matched-control group undergoing IVF-ICSI with fresh International Journal of Women’s Health 2010:2 94
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oocytes in a large ART program. They report that clinical 
and live-birth pregnancy rates per embryo transfer with 
oocyte cryopreservation are lower compared with success 
rates with fresh oocytes. However, no details were given 
about whether the ovarian stimulation was performed using 
human menopausal or rec-FSH.
Gelbaya et al35 assessed the implantation, pregnancy, 
and live-birth rates after FET in a natural or hormonal 
  control cycle. Two comparable groups of women with 
regular menstrual cycles: group A (n = 212) had FET in a 
natural cycle after spontaneous ovulation; group B (n = 205) 
had FET in a pituitary-desensitized hormonally controlled 
cycle. In group B, a GnRH agonist was commenced in the 
mid-luteal phase of the previous cycle and discontinued 
three days before embryo transfer. Oral estradiol valerate 
and a vaginal progesterone pessary were used to prepare the 
endometrium. Embryo transfer was carried out three days 
after detection of the endogenous luteinising hormone surge 
in group A and on day three of progesterone administration 
in group B. In the 212 women who had natural-cycle FET, 
172 embryo transfers were performed and 247 embryos 
replaced. The implantation rate was 14.1% (35/247). Twenty 
clinical pregnancies (20/172, 11.6%) were achieved. In 
the 205 women who had downregulated hormone replace-
ment cycle FET, 173 embryo transfers were performed and 
243 embryos replaced. The implantation rate was 13.5% 
(33/243). Eighteen clinical pregnancies (18/173, 10.2%) were 
achieved. There were no significant differences between the 
two groups with regard to the implantation, clinical preg-
nancy, or live-birth rates per cycle or per embryo transfer. The 
findings of Gelbaya et al35 suggest that both FET protocols are 
equally effective in terms of implantation rate and pregnancy 
outcome in women with regular menstrual cycles. However, 
no details were given about whether the ovarian stimulation 
was performed using human menopausal or rec-FSH.
Racowksy et al44 compared the cumulative pregnancy 
rates for fresh and frozen-thawed embryos and found no 
significant difference between rec-FSH and u-FSH in clinical 
pregnancy rates per started cycle [ﾭ44.1 (367/832) versus 
43.6% (248/569)], or delivery rates [ﾭ37.9% (315/832) versus 
35.5% (202/569)].
Using the agonist long protocol for downregulation, 
five trials provided extractable data for this review and 
meta-analysis. The characteristics of these trials are discussed 
below in detail.
Ziebe et al48 evaluated as part of a randomized, 
  assessor-blind, multinational trial conducted in 731 women 
undergoing IVF after stimulation with highly purified human 
menopausal gonadotropin (HP-hMG; MENOPUR, n = 363) or 
rec-FSH (rec-FSH; GONAL-F, n = 368). Ongoing preg-
nancy was the primary endpoint [ﾭHP-hMG 27% and rec-
FSH 22%; OR (95% CI) 1.25 (0.89–1.75)]. The live-birth, 
ongoing pregnancy, and ongoing implantation rates for top 
  quality embryos were higher with HP-hMG than rec-FSH 
[ﾭ48 versus 32% (P = 0.038), 48 versus 32% (P = 0.038), 
41 versus 27% (P = 0.032), respectively]. Both the proportion 
of embryos with at least 50% surviving blastomeres after 
  cryopreservation and of embryos resuming mitosis were 
more frequent with HP-hMG than with rec-FSH. A one-year 
followup of the cryopreserved embryos included data for 
178 patients (HP-hMG 89, rec-FSH 89) who had embryos 
thawed in the specified time period, of whom 142 patients 
(HP-hMG 69, rec-FSH 73) underwent 206 embryo transfer 
cycles (HP-hMG 93, rec-FSH 113) using 331 embryos 
(HP-hMG 145, rec-FSH 186). In the first cryocycle, the live-
birth rate was 9% in both the HP-hMG and rec-FSH groups. 
The live birth rate in the cryocycles with embryo transfer 
was 13% for HP-hMG and 10% for rec-FSH.
Seelig et al46 carried out a retrospective study with 
hMG (n = 194) and recFSH (n = 92) in a long-protocol 
or hMG (n = 16) or recFSH (n = 40) stimulation under 
  pituitary suppression with the GnRH antagonist cetrotide. 
The two-pronuclear oocytes were transferred after endo-
metrial preparation. Implantation rates in the freeze-thaw 
cycles were 5.6% (hMG) and 3.8% (rec-FSH) with two-
pronuclear oocytes from the long protocol, and 7% from 
the antagonist cycles, irrespective of whether hMG or 
recFSH was used. Pregnancy rates were similar, inde-
pendent of whether they resulted from the long protocol 
cycles with hMG (15.4%) or recFSH (13.1%), or from the 
antagonist protocol cycles with hMG (25.0%) or recFSH 
(17.5%).
Out et al42 conducted a prospective, randomized, 
  assessor-blind, multicenter (n = 18) study with infertile 
women undergoing IVF comparing rec-FSH (Org 32489, 
Puregon®) and u-FSH (Metrodin®). In total, 585 subjects 
received rec-FSH and 396 u-FSH. Ongoing pregnancy 
rates per attempt and transfer in the rec-FSH group were 
22.17% and 25.97%, respectively, and in the u-FSH group, 
18.22% and 22.02%, respectively. These differences 
were not statistically significant. Ongoing pregnancy 
rates including pregnancies resulting from frozen-thawed 
embryo cycles were 25.7% for rec-FSH and 20.4% for 
u-FSH (P  0.05). Subsequently, 117 and 73 subjects in 
the rec-FSH and u-FSH groups, respectively, underwent 
a natural cycle during which frozen-thawed embryos International Journal of Women’s Health 2010:2 95
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were replaced, resulting in 17 ongoing pregnancies in the 
rec-FSH group and five in the u-FSH group. A second “fro-
zen embryo” cycle was done in 26 and 15 women (“new 
women”, not coming from the previous group of 117 and 
73 women, respectively, who did not become pregnant), 
which resulted in seven additional pregnancies (five in the 
rec-USH and two in the u-FSH group). Eight women had a 
third frozen embryo cycle and two subjects a fourth, which 
did not result in ongoing pregnancies. The mean number 
of embryos transferred in the frozen embryo cycles was 
2.1 for both groups. In total, 22 additional pregnancies 
were obtained in the rec-FSH group, and seven in the u-
FSH group, resulting in cumulative ongoing pregnancy 
rates (adjusted for center) of 25.7% and 20.4% in favor 
of rec-FSH.
Kahn et al38 carried out a prospective, randomized, 
  comparative, cohort study which addressed issues of 
  pregnancy rate per couple over several cycles of treatment and 
the inclusion of pregnancies from frozen embryos resulting 
from the study cycles. In this trial, the take-home baby rate 
over three cycles of IVF treatment, including those babies 
conceived from frozen embryos, was 54/86 (62.8%) for 
women using rec-FSH (follitropin-beta) and 40/60 (66.7%) 
for those using u-FSH (P = 0.63).
Hompes et al37 carried out an open-label, prospective, 
  randomized study in which they studied the ongoing 
  pregnancy rates per started cycle of 629 patients, and reported 
rates of 26.3% and 25.2% for HP-hMG and rec-FSH, 
respectively (no statistically significant difference). Within 
the groups, the numbers of subjects with embryo transfer 
in cryo-cycles 1 and 2 were 19 and 1, respectively, in the 
HP-hMG group and were 31 and 4, respectively, in the 
rec-FSH group. The numbers of ongoing pregnancies in 
these cryocycles were 5/20 (25%) in the HP-hMG group 
and 4/35 (11.4%) in the rec-FSH. No statistically significant 
differences were observed for the ongoing pregnancy rates in 
the cryocycles. The same applies to the cumulative ongoing 
pregnancy rates, cumulative delivery rate, and cumulative 
live-birth rate (combining results of collecting cycle and 
one-year outcome of cryocycles).
Figure 2 shows the results from the meta-analysis of the 
above five studies, which show no evidence of a significant dif-
ference between the use of u-FSH versus rec-FSH regarding the 
live-birth rate (u-FSH 6/69 versus rec-FSH 7/73, OR = 0.90; 
95% CI = 0.29–2.82, P = 0.85) and the ongoing pregnancy 
rates (u-FSH 5/73 versus rec-FSH 17/117, OR = 0.43; 95% 
CI = 0.15–1.23, P = 0.12). Data on the clinical pregnancy, 
implantation, and miscarriage rates following FET were not 
available from the randomized trials. The cumulative live-birth 
rate did not demonstrate any significant differences between 
the use of u-FSH versus rec-FSH for ovarian stimulation, 
according to Ziebe et al48 and Hompes et al37 [ﾭ(u-FSH 105/363 
versus rec-FSH 91/368, OR = 1.24; 95% CI = 0.89–1.72, 
P = 0.20), (u-FSH 82/312 versus rec-FSH 75/317, OR = 1.15; 
95% CI = 0.80–1.65, P = 0.45), respectively].
The cumulative ongoing pregnancy rate also did not 
  demonstrate any significant differences between the use of 
u-FSH versus rec-FSH for ovarian stimulation, according 
to Hompes et al37 and Out et al42 [ﾭ(u-FSH 82/312 versus 
rec-FSH 80/317, OR = 1.06; 95% CI = 0.74–1.51, P = 0.76), 
(u-FSH 150/585 versus rec-FSH 87/396, OR = 1.22; 95% 
CI = 0.91–1.66, P = 0.19), respectively]. Also, the cumulative 
clinical pregnancy rates per woman did not demonstrate 
any significant differences between the use of u-FSH 
versus rec-FSH for ovarian stimulation, (u-FSH 20/60 
versus rec-FSH 37/86, OR = 0.66; 95% CI = 0.33–1.31, 
P = 0.24).
The retrospective study by Seelig et al46 provided data on 
the clinical pregnancy rate following the use of u-FSH versus 
rec-FSH in women undergoing ovarian stimulation in agonist 
and antagonist cycles. For women undergoing a long agonist 
protocol, the clinical pregnancy rate showed no evidence of 
a significant difference in effect between the use of u-FSH 
versus rec-FSH (u-FSH 30/195 versus rec-FSH 12/92, 
  OR = 1.21; 95% CI = 0.59–2.49, P = 0.60), respectively. 
Using the antagonist protocol, the clinical pregnancy rates 
were also similar between the two groups (u-FSH 4/16 versus 
rec-FSH 7/40, OR = 1.57; 95% CI = 0.39–6.34, P = 0.53, 
Figure 2).
Discussion
The results of this systematic review of the literature reveal 
no evidence of a significant difference between the clinical 
results following FET produced from stimulation cycles 
using u-FSH versus rec-FSH. It is also of importance that 
this review has demonstrated the dearth of information 
available in the literature on this subject, with most of the 
identified studies comparing only the transfer of embryos 
from the initial cycle, with minimal information regarding 
clinical outcomes following the transfer of frozen-thawed 
embryos.
Comparisons of different gonadotropin preparations 
regarding efficacy and safety as well as cost effectiveness 
are important issues in assisted reproduction. The cumulative 
pregnancy rate per cycle is strongly related to the number of 
oocytes retrieved, and therefore number of embryos available International Journal of Women’s Health 2010:2 96
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for transfer.51 Traditionally, ovarian stimulation protocols 
relied heavily on high doses of FSH to stimulate the largest 
cohort of follicles possible. This created two negative aspects 
of stimulation, a higher risk for the development of ovarian 
hyperstimulation syndrome, and an increased number of 
embryos that must either be transferred in the immediate cycle 
or discarded.52 Incorporation of cryopreservation of embryos 
has negated the latter because surplus embryos can be safely 
stored for future use. In centers where embryo cryopreser-
vation is routinely used, almost 50% of all implantations 
are done by FET.53 Therefore, trials of FSH efficacy should 
include the cumulative success rates following FET per 
cycle started instead of only embryos transferred in the first 
cycle.20,54
Over the past few years, the efficacy of different 
FSH preparations have been tested to determine the most 
  effective and safe product for use in human IVF. Today, 
the commercially available choices can be classified into 
highly-purified gonadotropins, which contain both FSH and 
luteinizing hormone, and HP-FSH and rec-FSH preparations. 
Due to the advanced purification and manufacturing 
  processes, the subcutaneous route of administration is 
available for all these products, which makes them more 
convenient and patient friendly.
In clinical trials, rec-FSH had been proposed to be 
  clinically more efficient than u-FSH (eg, Metrodin-
HP, Menogon).55 However, these products have been 
replaced with newer compounds with a higher concentra-
tion of glycosylated FSH (Fostimon®) and in the case of 
  gonadotropins, the addition of hCG. These modifications 
have shown that no single product has demonstrated clinical 
superiority over another product.4,5,56
Different aspects that may affect the implantation rate 
of frozen-thawed embryos have been tested over the years, 
including the use of GnRH agonist versus antagonist during 
ovarian stimulation, the type and components used during 
cryopreservation, and thawing techniques.57 Even so, to the 
best of our knowledge, and as demonstrated by the meticulous 
search of the literature, there are only a handful of studies that 
have investigated the effect of the type of FSH used during 
ovarian stimulation.
Conclusions
It seems that clinical pregnancy rate after FET is not influ-
enced by the type of gonadotropins used. With respect to 
cumulative rates, it is noted that no significant differences 
in live-birth rate, ongoing pregnancy rate, and clinical 
pregnancy rate for fresh cycles and no significant differences 
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Figure 2 Forest plot demonstrating clinical outcomes.
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in these rates for cryocycles implies no significant 
differences in the cumulative rates. Research should be 
directed to improving freezing and thawing techniques. 
At the present time there is insufficient evidence to sup-
port the use of one gonadotropin in preference to another. 
This review concludes that there is insufficient evidence to 
support the use of rec-FSH over urinary gonadotropins in 
ovarian stimulation prior to FET for women undergoing 
assisted reproductive technology.
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